CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Allopurinol

别嘌醇 杂质对照品Allopurinol Impurities

EPUSP31 个杂质条目31 impurity entries

本页汇总 别嘌醇 的 31 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 31 impurity reference standards of Allopurinol with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 别嘌醇(Allopurinol)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesForced Degradation and Stability-Indicating Study for the Binary Mixture of Allopurinol and Thioctic Acid Using Validated HPLC-DAD Method
    Journal of AOAC International · 2023 · El-Kafrawy DS et al.  ·  PMID 36847424  ·  DOI
  2. 杂质研究Impurity studiesLinear solvent strength model on porous graphitic carbon stationary phase using high temperature liquid chromatographic method for allopurinol related substances analysis
    Journal of pharmaceutical and biomedical analysis · 2024 · Soós B et al.  ·  PMID 38723557  ·  DOI
  3. 杂质研究Impurity studiesDevelopment and greenness assessment of a stability-indicating HPLC-DAD method for simultaneous determination of allopurinol and benzbromarone
    Drug development and industrial pharmacy · 2021 · El-Kafrawy DS et al.  ·  PMID 33899636  ·  DOI
  4. 分析方法Analytical MethodsSpectrophotometric determination of lesinurad and allopurinol in recently approved FDA pharmaceutical preparation
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2021 · Mohamed AA et al.  ·  PMID 33160135  ·  DOI
  5. 分析方法Analytical MethodsSample preparation and quantification of polar drug, allopurinol, in human plasma using LCMSMS
    European journal of mass spectrometry (Chichester, England) · 2022 · Wong EYL et al.  ·  PMID 35668610  ·  DOI

别嘌醇 —— 原料药与杂质对照品Allopurinol — drug substance & impurities

共 32 个条目(含原料药本体)32 items incl. the drug substance
Allopurinol structure
EP原料药 APIAPI
别嘌醇Allopurinol
Allopurinol
CAS No.315-30-0
Chemical FormulaC5H4N4O
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 1 Sulfate(Allopurinol EP Impurity A Sulfate)(Allopurinol USP Related Compound A  Sulfate) structure
EPA
别嘌醇杂质1 硫酸盐(别嘌醇EP杂质A 硫酸盐)(别嘌醇USP相关化合物A 硫酸盐)Allopurinol Impurity 1 Sulfate(Allopurinol EP Impurity A Sulfate)(Allopurinol USP Related Compound A Sulfate)
Allopurinol Impurity 1 Sulfate(Allopurinol EP Impurity A Sulfate)(Allopurinol USP Related Compound A Sulfate)
CAS No.27511-79-1
Chemical FormulaC4H6N4O·H2SO4
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol EP Impurity A structure
EPA
别嘌醇杂质1(别嘌醇EP杂质A)(别嘌醇USP相关化合物A)Allopurinol EP Impurity A
Allopurinol EP Impurity A
CAS No.5334-31-6
Chemical FormulaC4H6N4O
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol EP Impurity B structure
EPB
别嘌醇杂质2(别嘌醇EP杂质B)(别嘌醇USP相关化合物B)Allopurinol EP Impurity B
Allopurinol EP Impurity B
CAS No.22407-20-1
Chemical FormulaC5H6N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol EP Impurity C structure
EPC
别嘌醇杂质3 (别嘌醇EP杂质C) (别嘌醇USP相关化合物C)Allopurinol EP Impurity C
Allopurinol EP Impurity C
CAS No.1346604-13-4
Chemical FormulaC6H6N6O
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol EP Impurity D (Allopurinol USP Related Compound D) structure
EPD
别嘌醇杂质4 (别嘌醇EP杂质D)(别嘌醇USP相关化合物D)Allopurinol EP Impurity D (Allopurinol USP Related Compound D)
Allopurinol EP Impurity D (Allopurinol USP Related Compound D)
CAS No.6994-25-8
Chemical FormulaC6H9N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol EP Impurity E structure
EPE
别嘌醇杂质5 (别嘌醇EP杂质E) (别嘌醇USP相关化合物E)Allopurinol EP Impurity E
Allopurinol EP Impurity E
CAS No.31055-19-3
Chemical FormulaC7H9N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol USP Related Compound F structure
USPF
别嘌醇杂质6 (别嘌醇USP相关化合物F)Allopurinol USP Related Compound F
Allopurinol USP Related Compound F
CAS No.321571-07-7
Chemical FormulaC12H14N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Oxypurinol-13C-15N2 structure
—
Oxypurinol-13C-15N2
CAS No.1217036-71-9
Chemical FormulaC5H4N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Riboside structure
—
别嘌醇杂质9Allopurinol Riboside
Allopurinol Riboside
CAS No.16220-07-8
Chemical FormulaC10H12N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Oxypurinol structure
—
别嘌醇杂质14Oxypurinol
Oxypurinol
CAS No.2465-59-0
Chemical FormulaC5H4N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Oxypurinol-13C3-15N3 structure
—
Oxypurinol-13C3-15N3
CAS No.—
Chemical FormulaC213C3H4N15N3O2
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Allopurinol structure
—
N-Nitroso Allopurinol
CAS No.—
Chemical FormulaC5H3N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 1 structure
1
别嘌醇杂质1Allopurinol Impurity 1
Allopurinol Impurity 1
CAS No.—
Chemical FormulaC8H8N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 3 structure
3
别嘌醇杂质3Allopurinol Impurity 3
Allopurinol Impurity 3
CAS No.—
Chemical FormulaC6H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 4 Disodium Salt structure
4
别嘌醇杂质4Allopurinol Impurity 4 Disodium Salt
Allopurinol Impurity 4 Disodium Salt
CAS No.—
Chemical FormulaC13H14N2O4.2Na
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 5 structure
5
奥拉西坦杂质31Allopurinol Impurity 5
Allopurinol Impurity 5
CAS No.4862-18-4
Chemical FormulaC6H12N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 6 structure
6
别嘌醇杂质6Allopurinol Impurity 6
Allopurinol Impurity 6
CAS No.—
Chemical FormulaC4H5N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 7 structure
7
别嘌醇杂质7Allopurinol Impurity 7
Allopurinol Impurity 7
CAS No.16617-46-2
Chemical FormulaC4H4N4
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 8 structure
8
别嘌醇杂质8Allopurinol Impurity 8
Allopurinol Impurity 8
CAS No.5334-56-5
Chemical FormulaC6H6N4O
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 10 structure
10
别嘌醇杂质10Allopurinol Impurity 10
Allopurinol Impurity 10
CAS No.34397-00-7
Chemical FormulaC8H8N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 11 structure
11
别嘌醇杂质11Allopurinol Impurity 11
Allopurinol Impurity 11
CAS No.1194374-10-1
Chemical FormulaC8H13N3·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 13 structure
13
别嘌醇杂质13Allopurinol Impurity 13
Allopurinol Impurity 13
CAS No.19750-02-8
Chemical FormulaC6H9N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 15 structure
15
别嘌醇杂质15Allopurinol Impurity 15
Allopurinol Impurity 15
CAS No.83-39-6
Chemical FormulaC5H6N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 17 structure
17
别嘌醇杂质17Allopurinol Impurity 17
Allopurinol Impurity 17
CAS No.853754-87-7
Chemical FormulaC4H5N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 22 structure
22
别嘌醇杂质22Allopurinol Impurity 22
Allopurinol Impurity 22
CAS No.2303964-80-7
Chemical FormulaC4H6N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 23 structure
23
别嘌醇杂质23Allopurinol Impurity 23
Allopurinol Impurity 23
CAS No.74786-62-2
Chemical FormulaC4H4N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 27 structure
27
别嘌醇杂质27Allopurinol Impurity 27
Allopurinol Impurity 27
CAS No.22630-09-7
Chemical FormulaC13H25N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 29 structure
29
别嘌醇杂质29Allopurinol Impurity 29
Allopurinol Impurity 29
CAS No.35534-35-1
Chemical FormulaC9H19NO3
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 30 structure
30
别嘌醇杂质30Allopurinol Impurity 30
Allopurinol Impurity 30
CAS No.777835-45-7
Chemical FormulaC4H4N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 32 structure
32
别嘌醇杂质32Allopurinol Impurity 32
Allopurinol Impurity 32
CAS No.26753-52-6
Chemical FormulaC10H13N4O8P
Purity>95%询价On request
10mg25mg50mg100mg
Allopurinol Impurity 38 structure
38
别嘌醇杂质38Allopurinol Impurity 38
Allopurinol Impurity 38
CAS No.343570-58-1
Chemical FormulaC10H14N2O3
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

别嘌醇 —— 研究文献与合成路线Allopurinol — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 别嘌醇 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Allopurinol. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Forced Degradation and Stability-Indicating Study for the Binary Mixture of Allopurinol and Thioctic Acid Using Validated HPLC-DAD Method
    El-Kafrawy DS, Abdelhamid AG, Abdel-Khalek MM, et al. · Journal of AOAC International · 2023 · 被引 1cited 1
  2. Chronic allopurinol and adenine therapy in Duchenne muscular dystrophy: effects on muscle function, nucleotide degradation, and muscle ATP and ADP content
    Bertorini TE, Palmieri GM, Griffin J, et al. · Neurology · 1985 · 被引 21cited 21
  3. Automated fluorimetric determination of the genotoxic impurity hydrazine in allopurinol pharmaceuticals using zone fluidics and on-line solid phase extraction
    Tzanavaras PD, Themistokleous S, Zacharis CK · Journal of pharmaceutical and biomedical analysis · 2020 · 被引 5cited 5
  4. Different spectrophotometric methods for simultaneous determination of lesinurad and allopurinol in the new FDA approved pharmaceutical preparation; additional greenness evaluation
    Abdelazim AH, Abourehab MAS, Abd Elhalim LM, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2023 · 被引 13cited 13
  5. Spectrophotometric determination of lesinurad and allopurinol in recently approved FDA pharmaceutical preparation
    Mohamed AA, El-Olemy A, Ramzy S, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2021 · 被引 10cited 10
  6. Developing, optimizing, and assessing a green electrophoretic method for determination of benzbromarone and allopurinol with its active metabolite in biological and pharmaceutical matrices
    Essam HM, Mohamed HM · Journal of separation science · 2021 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. Preparation, useful for the treatment of equine Cushing's syndrome, comprises allopurinol
    — · 公开号 DE102008034739DE102008034739 · 2010
  2. ALLOPURINOL-CONTAINING MEDICINAL PREPARATION
    TERADA HIROSHI, MAKINO KIMIKO · 公开号 JP2006036700JP2006036700 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

别嘌醇 杂质谱研究要点Allopurinol — impurity profiling notes

下面这些是拿到 别嘌醇 的 32 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 32 impurity entries for Allopurinol, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances